. 2023 Jul 26;13:12137. doi: 10.1038/s41598-023-39369-y

Table 5.

Summary table of principal findings.

Cell type	Pre-treatment conditions	Treatment conditions	Outcomes
Cell type	Pre-treatment conditions	Treatment conditions	Proliferation	Myofibroblast markers
HCFs from patients with diabetic cardiomyopathy	Long-term culture on stiff substrates (3 GPa, ≤ 10 passages)	Stiff substrate (3 GPa) ± TGF-β ± TGF-βRi	No change	No change
HCFs from patients with diabetic cardiomyopathy		Soft substrate (25 kPa, 2 kPa) ± TGF-β ± TGF-βRi	No change	No change
hiPSC-cFbs	Quiescent hiPSC-cFbs (2 week culture with TGF-βRi)	TGF-β	Reduced	Increased
	Quiescent hiPSC-cFbs (2 week culture with TGF-βRi)	TGF-βRi	No change	No change
	Activated hiPSC-cFbs (2 week culture without TGF-βRi)	TGF-β	No change	No change
	Activated hiPSC-cFbs (2 week culture without TGF-βRi)	TGF-βRi	No change	No change

hiPSC-cFbs human induced pluripotent stem cell derived cardiac fibroblasts, TGF-β transforming growth factor-beta, TGF-βRi transforming growth factor-beta receptor inhibitor.